脐带间充质干细胞治疗熊去氧胆酸应答不佳的原发性胆汁性胆管炎的临床观察

目的探讨脐带间充质干细胞（UC-MSCs）输注治疗熊去氧胆酸（UDCA）应答不佳的原发性胆汁性胆管炎（PBC）患者的安全性和有效性，分析影响UC-MSCs疗效应答的相关因素。 方法选取解放军总医院第五医学中心2010年8月至2017年10月接受UC-MSCs输注治疗UDCA应答不佳的PBC患者29例。患者均以4周为间隔给予3次外周静脉输注细胞1.0×10⁶个/kg。通过实验室指标、生命体征及不良事件发生情况评估UC-MSCs治疗的安全性。通过患者临床症状、肝功指标和Child-Pugh评分评估治疗的有效性。以"巴黎Ⅰ标准"作为疗效标准，评价患者UC-MSCs治疗后的疗效应答情况，比较有效患者及无效患者基线临床症状和肝脏功能差异，分析影响UC-MSCs疗效的相关因素。采用独立样本t检验分析年龄；采用Mann-Whitney U检验比较两组UDCA治疗时间、激素治疗时间、实验室数据等，采用Wilcoxon秩和检验比较组间数据；采用χ²检验比较性别、临床症状和Child-Pugh分级等指标。多因素Cox回归分析对影响UC-MSCs疗效的相关因素。 结果1例患者在治疗后因合并严重感染出现高热，所有患者未出现UC-MSCs相关严重不良事件。UC-MSCs输注后与基线相比，患者的血清碱性磷酸酶（ALP）[281.00 （182.50，428.50）比201.00 （149.50，402.00）]、γ-谷氨酰转移酶（GGT）[156.00 （73.00，390.00）比84.00 （43.50，312.50）]、总胆固醇（TC）[5.10 （3.14，7.69）比3.94 （3.00，6.01）]均下降（P < 0.05）。其中，9例（31﹪）患者治疗后疗效明显，达到"巴黎Ⅰ标准"，与无效组患者基线相比，有效组患者天冬氨酸转氨酶（AST）[93.50 （77.75，100.75）比53.00 （46.00，78.00）]、ALP[342.00 （237.25，516.00）比185.00 （152.50，295.50）]、总胆红素（TBIL）[58.50 （33.45，69.33）比13.10 （11.25，20.25）]均下降（P < 0.05）。多因素Cox回归分析显示，血清TBIL是影响UC-MSCs疗效的重要独立因素[HR为0.817 （95﹪CI：0.715 ~ 0.935），P < 0.05]。 结论UC-MSCs输注对UDCA治疗应答不佳的PBC患者是安全可行的且耐受性良好，部分患者肝功能得到一定的改善。血清TBIL是影响UC-MSCs治疗疗效的独立重要因素，提示在疾病进展早期TBIL较低的阶段进行UC-MSCs治疗可能有效改善和减缓患者疾病进程。     

自噬参与原发性胆汁性胆管炎患者Th17/ Treg免疫失衡的研究

目的:Th17/Treg免疫失衡在原发性胆汁性胆管炎(PBC)的发病机制中起到关键作用。自噬是调节T细胞稳态的重要环节。本研究旨在探索自噬对PBC患者Th17/Treg免疫失衡的影响。方法:选取20例初次诊断的PBC患者,20例健康对照者,收集其外周血单个核细胞(PBMCs)。利用流式细胞术检测PBC患者与健康对照者PBMCs中Th17和Treg细胞分布及其胞内自噬的水平,进一步体外利用氯喹抑制自噬,证实自噬对PBC患者Th17/Treg平衡的影响。结果:相较于健康对照者,PBC患者Th17细胞占CD4~+T比例上升(P0.05),且血清中IL-17含量较高(P0.01);Treg细胞比例下降(P0.05),且血清中TGF-β含量较低(P0.01)。而PBC患者Th17细胞和Treg细胞内自噬水平均升高。另外,体外实验结果证实,自噬抑制剂氯喹能够有效地恢复PBC患者PBMCs中Th17/Treg平衡。结论:异常活化的自噬可导致PBC患者Th17/Treg免疫失衡,抑制自噬能够在体外恢复此平衡。因此,对异常自噬的干预可能将成为PBC疾病治疗的新方法。     

熊去氧胆酸联合非诺贝特对原发性胆汁性胆管炎的临床疗效及安全性

摘要 目的：分析熊去氧胆酸联合非诺贝特对原发性胆汁性胆管炎无熊去氧胆酸生化反应的临床疗效及安全性。方法：151例原发性胆汁性胆管炎无熊去氧胆酸患者按随机数表法分为73例对照组和78例研究组。对照组在常规治疗基础上给予安慰剂联合熊去氧胆酸治疗,研究组在常规基础上给予非诺贝特联合熊去氧胆酸治疗,两组均持续治疗12个月。比较两组临床疗效,肝功能,血脂指标,肝纤维化指标,免疫球蛋白G（IgG）、免疫球蛋白M（IgM）,瘙痒及乏力评分,不良反应发生情况。结果：治疗后,研究组总有效率高于对照组,比较差异有统计学意义（P<0.05）。治疗后,两组肝功能指标均降低,研究组低于对照组,比较有统计学意义（P<0.05）。治疗后,两组总胆固醇（TC）、甘油三酯（TG）均降低,研究组低于对照组,比较有统计学意义（P<0.05）,两组治疗前后低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）比较无统计学意义（P>0.05）。治疗后,两组肝纤维化指标均降低,研究组低于对照组,比较有统计学意义（P<0.05）。治疗后,两组IgG、IgM均降低,研究组低于对照组,比较有统计学意义（P<0.05）。治疗后,两组瘙痒、乏力评分均降低,研究组低于对照组,比较有统计学意义（P<0.05）。两组不良反应发生率比较差异无统计学意义（P>0.05）。结论：熊去氧胆酸联合非诺贝特对原发性胆汁性胆管炎无熊去氧胆酸生化反应的疗效较好,能够改善肝功能,且未明显增加药物不良反应。     

原发性胆汁性肝硬化家系成员的发病及机制初探

目的:研究原发性胆汁性肝硬化(PBC)家系患者发病时的临床表现、生化指标及人类白细胞抗原(HLA)基因分型的特征,分析该疾病的发病机制,以提高对该病的认识。方法:分别用临床生化分析试剂盒、间接免疫荧光法、免疫印迹法和微阵列聚合酶链式反应(PCR)等技术对收集的31个家系129例一级亲属进行生化指标、自身抗体和HLAⅡ基因分型的相关检测。结果:5个家系出现免疫异常,表现在抗核抗体(ANA)阳性,但仅有一个家系的一个成员出现抗线粒体抗体(AMA)M2型阳性,可诊断为PBC。其中,发现免疫异常的5个家系中2例一级亲属出现肝功能异常,两个家系发现HLAⅡ-DRB1(*08)基因型,另外两个家系共同存在HLAⅡ-DRB1(*07)基因型。结论:PBC具有一定的家族聚集性,其发病可能与HLAⅡ-DRB1(*08)密切相关。     

贝飞达对原发性胆汁性肝硬化患者细胞因子的影响

目的探讨微生态调节剂对原发性胆汁性肝硬化（PBC）的影响。方法34例PBC患者为我院住院患者,均有肝功能异常,随机分为2组,一组为常规治疗组,给予糖皮质激素类、熊去氧胆酸及其他免疫抑制／增强剂药物治疗,另一组为贝飞达治疗组,在常规治疗基础上加用贝飞达。经过1个月的治疗,采血检测细胞因子及肝功能,对结果进行统计学处理。结果贝飞达治疗组同常规治疗组进行比较,在降低细胞因子水平改善肝功能方面差异有显著性。结论贝飞达通过调整肠道菌群,控制内毒素血症,可以调整原发性胆汁性肝硬化患者的免疫功能,改善肝功能。     

熊去氧胆酸治疗原发性胆汁性肝硬化临床观察

目的探讨熊去氧胆酸治疗原发性胆汁性肝硬化的临床效果。方法选取某医院于2014年7月至2015年7月收治的原发性胆汁性肝硬化患者98例作为临床研究对象,随机将患者分为观察组和对照组,每组49例。两组患者均给予基础治疗,之后对照组患者采用通胆汤进行治疗,观察组患者在对照组的基础上加用熊去氧胆酸进行治疗。比较两组患者的治疗效果。结果根据分析结果,观察组患者的完全反应率明显高于对照组,并且肝功能指标明显优于对照组,比较结果具有显著差异性(P0.05)。结论熊去氧胆酸治疗原发性胆汁性肝硬化的临床效果良好,值得推广使用。     

原发性胆汁性肝硬化的药物治疗进展

原发性胆汁性肝硬化(Primary Biliary Cirrhosis,PBC)是一种以胆汁淤积及慢性非化脓性破坏性胆管炎为特点的自身免疫介导的慢性肝脏病。熊去氧胆酸(UDCA)作为PBC患者的首选治疗药物可使患者的生化指标、存活指标以及组织学等都得以改善。尽管如此,PBC的治疗仍是临床医师的一大难题,大约40%的PBC患者对UDCA的治疗仅获得了不完全应答,而肝移植则为晚期PBC患者治疗之首选。本文简要介绍近些年治疗PBC药物的新进展,包括熊去氧胆酸、布地奈德、免疫抑制剂、贝特类、6α-乙基鹅去氧胆酸、利妥昔单抗以及抗逆转录病毒药物等,期望为PBC的治疗提供帮助。     

原发性胆汁性肝硬化患者外周血淋巴细胞亚群的检测及其意义

目的:检测原发性胆汁性肝硬化(PBC)患者外周血淋巴细胞亚群,探讨其与PBC发病的关系.方法:采用流式细胞术检测PBC患者及正常人外周血中CD3+、CD3+ CD4+、CD3+CD8+、CD4/CD8、CD3-CD 16+/CD56+、CD3+HLA-DR+细胞水平.结果:与对照组比较,PBC组CD3+CD8+、CD3+HLA-DR+细胞百分比明显减低(P＜0.05),CD3-CD 19+、CD3-CD 16+/56+细胞、CD4+/CD8+明显增高(P＜0.05),CD3+、CD3+CD4+细胞均有所升高,但无显著性差异(P＞0.05).结论:PBC患者存在免疫功能紊乱.T淋巴细胞亚群的改变和NK细胞比例减少,导致B细胞功能亢进,产生多种自身抗体,在PBC的发病机理中起重要作用.     

免疫球蛋白在原发性胆汁性肝硬化与自身免疫性肝炎组织中的表达及意义

目的:原发性胆汁性肝硬化(PBC)与自身免疫性肝炎(AIH)的临床表现存在相似性,因而不易鉴别及诊断。本研究对免疫球蛋白在PBC和AIH中的表达情况进行比较并分析其意义,为两种疾病的鉴别和诊断积累临床资料。方法:选取2011年10月-2012年10月在我院接受治疗的原发性胆汁性肝硬化患者20例作为PBC组,另选取20例同期入院治疗的自身免疫性肝炎患者作为AIH组。利用免疫组化法检测两组患者病变组织中免疫球蛋白IgM和IgG的表达水平,比较两组细胞的阳性表达率,并对阳性细胞含量进行评分。结果:PBC组:17例患者显示IgM阳性(85%),3例患者显示IgG阳性(15%),IgM与IgG比值1,IgM评分为3.2±0.8,IgG评分为1.5±0.6;AIH组:18例患者显示IgG阳性(90%),2例患者显示IgM阳性(10%),IgM与IgG比值1,IgM评分为1.2±0.7,IgG评分为2.4±0.9。PBC组的IgM评分明显高于AIH组,而AIH组的IgG评分则明显高于PBC组,差异具有统计学意义(P0.05)。结论:检测IgG和IgM的表达水平对原发性胆汁性肝硬化与自身免疫性肝炎的临床诊断具有较高的敏感性和特异性,可作为鉴别两种疾病的依据之一,值得进一步推广应用。     

维生素D在自身免疫性肝病中的研究进展

维生素D是一种人体必需的脂溶性维生素,其除了可调节钙磷代谢,参与骨骼生长外,还可通过调节免疫细胞增殖分化和抗炎抗纤维化等参与多种免疫性疾病的发生发展。自身免疫性肝病(autoimmune liver disease,AILD)是由自身免疫反应引起的一组肝脏炎症性病变,有研究发现维生素D与AILD存在相关性,AILD患者血清中维生素D水平普遍降低,补充血清维生素D可降低肝损伤和肝纤维化程度。因此,探究维生素D在AILD发生发展中的作用具有一定的临床价值。本文对维生素D在AILD中的研究进展作一阐述。     

Role of biliary brush cytology in primary sclerosing cholangitis

OBJECTIVE: To assess the role of brush cytology in the routine evaluation of patients with primary sclerosing cholangitis (PSC). STUDY DESIGN: From January 1995 to June 2000, 64 brush cytology specimens were obtained from 21 patients who had at least one cytologic sample obtained during endoscopic retrograde cholangiography. All patients had a diagnosis of primary sclerosing cholangitis. Cases were classified as benign, atypical or malignant according to major cytologic criteria (nuclear contour and chromatin irregularities) and minor cytologic criteria (polarity, cellularity, nuclear enlargement, mitosis, increased nuclear/cytoplasmic ratio) used by us to diagnose biliary brush cytology. Follow-up was available in all cases. RESULTS: Diagnoses were benign (13), atypical (5) and malignant (3) on cytology. Follow-up of the 13 benign cases showed bile duct stones (2), gallbladder adenocarcinoma at cholecystectomy (1), ascending cholangitis (1) and clinically/cytologically by benign follow-up (9). Five of 13 benign cases had subsequent liver transplantation for liver failure, with explants showing changes of primary sclerosing cholangitis. Of the 3 malignant cases, 1 had carcinoma in situ on biopsy, with the explanted liver showing high grade dysplasia; the second patient had cholangiocarcinoma on explant; and the third had hepatocellular carcinoma on liver five needle aspiration. The 5 patients with atypical cytology were reclassified on review as reactive (3) and atypical not otherwise specified (2). Follow-up showed benign disease in 3 of 3 atypical cases reclassified as reactive; 2 of 2 reclassified as atypical not otherwise specified showed low grade dysplasia in the explant. CONCLUSION: The overall incidence of malignancy was low (3 of 21) in patients with PSC. Bile duct brushing is a sensitive method of detecting neoplasia in the setting of PSC when well-defined cytologic criteria are applied.     

The role of Helicobacter spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis

Helicobacter species DNA has been detected in liver tissue of patients affected by primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). To investigate a potential causative relation between Helicobacter species and PBC/PSC, we compared the presence of Helicobacter species-specific DNA in liver tissue of patients with PBC/PSC (n=18/n=13) with those of a control group of patients with various liver diseases with known cause (n=29). A PCR with Helicobacter genus-specific 16S rRNA primers was performed on DNA isolated from paraffin embedded liver tissue. Control patients had hepatitis-B (n=9), alcoholic cirrhosis (n=14), or non-cirrhotic metabolic liver disease (n=6). There was no significant difference between the incidence of Helicobacter spp.-specific DNA in PBC/PSC (9/31; 29%) and the control group (10/29; 34%). Sequence analysis confirmed Helicobacter spp. DNA. Because Helicobacter spp. DNA can be found in approximately one-third of all samples tested, it is unlikely that PSC and PBC are caused by Helicobacter infection.     

Emperipolesis mediated by CD8+ T cells correlates with biliary epithelia cell injury in primary biliary cholangitis

Primary biliary cholangitis (PBC) is an autoimmune disease characterized by chronic destruction of the bile ducts. A major unanswered question regarding the pathogenesis of PBC is the precise mechanisms of small bile duct injury. Emperipolesis is one of cell‐in‐cell structures that is a potential histological hallmark associated with chronic hepatitis B. This study aimed to clarify the pathogenesis and characteristics of emperipolesis in PBC liver injury. Sixty‐six PBC patients, diagnosed by liver biopsy combined with laboratory test, were divided into early‐stage PBC (stages I and II, n = 39) and late‐stage PBC (stages III and IV, n = 27). Emperipolesis was measured in liver sections stained with haematoxylin‐eosin. The expressions of CK19, CD3, CD4, CD8, CD20, Ki67 and apoptosis of BECs were evaluated by immunohistochemistry or immunofluorescence double labelling. Emperipolesis was observed in 62.1% of patients with PBC, and BECs were predominantly host cells. The number of infiltrating CD3⁺ and CD8⁺ T cells correlated with the advancement of emperipolesis (R² = 0.318, P < .001; R² = 0.060, P < .05). The cell numbers of TUNEL‐positive BECs and double staining for CK19 and Ki67 showed a significant positive correlation with emperipolesis degree (R² = 0.236, P < .001; R² = 0.267, P < .001). We conclude that emperipolesis mediated by CD8⁺ T cells appears to be relevant to apoptosis of BEC and thus may aggravate the further injury of interlobular bile ducts.     

沙眼衣原体感染动物模型的研究及应用

沙眼衣原体(Chlamydia trachomatis,Ct)是一种严格细胞内寄生且具有独特发育周期的革兰阴性菌,感染人类生殖道等部位后会引起严重病理损伤。关于Ct感染人类宿主细胞的具体致病机制及疫苗的研制还有待深入研究。动物模型在Ct的基础研究方面具有较高的科研应用价值。就常见的小鼠、豚鼠、灵长类等Ct感染动物模型及应用作一综述。     

S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis

Background and Aims

Bile analysis has the potential to serve as a surrogate marker for inflammatory and neoplastic disorders of the biliary epithelium and may provide insight into biliary pathophysiology and possible diagnostic markers. We aimed to identify biliary protein markers of patients with primary sclerosing cholangitis (PSC) by a proteomic approach.

Methods

Bile duct-derived bile samples were collected from PSC patients (n = 45) or patients with choledocholithiasis (n = 24, the control group). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to analyse the proteins, 2-D-gel patterns were compared by densitometry, and brush cytology specimens were analysed by RT-PCR.

Results

A reference bile-duct bile proteome was established in the control group without signs of inflammation or maligancy comprising a total of 379 non-redundant biliary proteins; 21% were of unknown function and 24% had been previously described in serum. In PSC patients, the biliary S100A9 expression was elevated 95-fold (p<0.005), serum protein expression was decreased, and pancreatic enzyme expression was unchanged compared to controls. The S100A9 expression was 2-fold higher in PSC patients with high disease activity than in those with low activity (p<0.05). The brush cytology specimens from the PSC patients with high disease activity showed marked inflammatory activity and leukocyte infiltration compared to the patients with low activity, which correlated with S100A9 mRNA expression (p<0.05).

Conclusions

The bile-duct bile proteome is complex and its analysis might enhance the understanding of cholestatic liver disease. Biliary S100A9 levels may be a useful marker for PSC activity, and its implication in inflammation and carcinogenesis warrants further investigation.     

Atypical primary biliary cholangitis results in vanishing bile duct syndrome with cutaneous xanthomas: a case report

Former single center studies indicated that HER2 assessment with two primary tumor blocks (dual block HER2 assessment) could be an efficient and practical approach to overcome the adverse impact of heterogeneity and acquire a HER2 positive rate in gastric cancer (GC). This multicenter prospective clinical trial (NCT 02843412) was launched to verify its value and generality. A total of 3806 participants with primary GCs have been enrolled from 8 hospitals in China. Two primary tumor blocks were selected and recorded as block 1 and block 2 after histological evaluation. An HER2 (4B5) rabbit monoclonal antibody was used for the immunohistochemistry (IHC) analysis. In total patients, HER2 IHC positive (3+) rate with dual block assessment (9.4%) was higher than that with single block assessment (block 1: 7.8%, block 2: 7.8%) (P < 0.001). Compared with single-block assessment, dual-block assessment increased the positive rate by approximate 20%. Similarly, HER2 equivocal (2+) rate was increased in dual block assessment (25.8%), which was higher than that in single block assessment (block 1: 20.3%, block 2: 20.9%) (P < 0.001). Conversely, dual block assessment demonstrated a lower HER2 negative (0/1+) rate (64.8%) than single block assessment (block1: 71.9%, block 2: 71.3%) (P < 0.001). These findings were also confirmed in individual hospitals. Dual block HER2 assessment effectively increased HER2 IHC positive rate in resected specimens of GC. We recommended dual block HER2 assessment be promoted in routine clinical practice in GC. ClinicalTrials.gov, NCT 02843412 . Registered 1 July 2016 - Retrospectively registered.     

X-ray diagnosis of primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) should be regarded as a disease of the bile tracts which is difficult to diagnose rather than a rare disease. Combined radiodiagnostic investigation in the preoperative period is of great importance. Direct methods of an induced contrast study of the biliferous system (transcutaneous transhepatic cholangiography, endoscopic retrograde pancreatocholangiography) play a major role in the diagnosis of PSC. The authors present 11 cases, describing in detail x-ray semiotics of various sites of PSC and its differential diagnosis with similar diseases.